Mesenchymal stem cells

Intervention9 papers6 findingsMeSH D059630

Animals2

Outcomes

Pro-inflammatory cytokines

downin humans1High certainty

1 study

Mesenchymal stem cells decrease pro-inflammatory cytokines in humans.
Reviewaging frailty
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review · International journal of molecular sciences · 25 Aug 2026

Pro-inflammatory cytokines →

Physical function

upin humans1High certainty

1 study

Mesenchymal stem cells improve physical function in humans.
Reviewaging frailty
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review · International journal of molecular sciences · 25 Aug 2026

6-minute walk distance

upin humans1High certainty

1 study

Mesenchymal stem cells improve 6-minute walk distance in humans.
Reviewaging frailtynine months
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review · International journal of molecular sciences · 25 Aug 2026

6-minute walk distance →

Healthspan

upin reviews1

1 study

Mesenchymal stem cells improve healthspan.
Review
Engineering Mesenchymal Stem Cells for Healthspan-Relevant Applications: Therapeutic Potential, Challenges, and Future Solutions · Cells · 11 Aug 2026

Inflammation

downin reviews1

1 study

Mesenchymal stem cells inhibit inflammation.
Review
Engineering Mesenchymal Stem Cells for Healthspan-Relevant Applications: Therapeutic Potential, Challenges, and Future Solutions · Cells · 11 Aug 2026

Inflammation →

Cellular senescence

downin reviews1

1 study

Mesenchymal stem cells inhibit cellular senescence.
Review
Engineering Mesenchymal Stem Cells for Healthspan-Relevant Applications: Therapeutic Potential, Challenges, and Future Solutions · Cells · 11 Aug 2026

Cellular senescence →

Trials

128

In trials

Aplastic Anemia
Phase 4 · Status unknown · 4 trials
Graft vs Host Disease
Phase 3 · Completed · 7 trials
Knee osteoarthritis
Phase 3 · Recruiting · 7 trials
Huntington's disease
Phase 2/3 · Status unknown · 3 trials
Spinal cord injury
Phase 2/3 · Terminated · 3 trials
Multiple sclerosis
Phase 2 · Completed · 7 trials

40 of 63

Systemic lupus erythematosus
Phase 2 · Completed · 5 trials
Diabetes mellitus
Phase 2 · Recruiting · 4 trials
Osteoarthritis
Phase 2 · Recruiting · 4 trials
Autoimmune disease
Phase 2 · Recruiting · 3 trials
Bronchiolitis Obliterans Syndrome
Phase 2 · Status unknown · 3 trials
Parkinson's disease
Phase 2 · Results posted · 3 trials
Type 1 diabetes
Phase 2 · Status unknown · 3 trials
COVID-19
Phase 2 · Completed · 2 trials
Hematologic Diseases
Phase 2 · Status unknown · 2 trials
Ischemia
Phase 2 · Results posted · 2 trials
Left ventricular dysfunction
Phase 2 · Results posted · 2 trials
Lupus nephritis
Phase 2 · Recruiting · 2 trials
Safety Issues
Phase 2 · Status unknown · 2 trials
Type 2 diabetes
Phase 2 · Recruiting · 2 trials
Diabetic nephropathy
Phase 2 · Completed · 1 trial
Heart failure
Phase 2 · Results posted · 1 trial
Insulin resistance
Phase 2 · Status unknown · 1 trial
Multiple myeloma
Phase 2 · Terminated · 1 trial
Myelodysplastic syndrome
Phase 2 · Terminated · 1 trial
non-Hodgkin lymphoma
Phase 2 · Terminated · 1 trial
Crohn's disease
Phase 1/2 · Terminated · 6 trials
Chronic limb-threatening ischemia
Phase 1/2 · Completed · 3 trials
Diabetic Foot
Phase 1/2 · Status unknown · 3 trials
Amyotrophic lateral sclerosis
Phase 1/2 · Completed · 2 trials
Fibrosis
Phase 1/2 · Completed · 2 trials
Fistula
Phase 1/2 · Terminated · 2 trials
Liver cirrhosis
Phase 1/2 · Status unknown · 2 trials
Musculoskeletal disease
Phase 1/2 · Results posted · 2 trials
Stem Cell Transplant
Phase 1/2 · Status unknown · 2 trials
Acute kidney injury
Phase 1/2 · Status unknown · 1 trial
Acute liver failure
Phase 1/2 · Completed · 1 trial
Acute myocardial infarction
Phase 1/2 · Completed · 1 trial
Alopecia
Phase 1/2 · Enrolling by invitation · 1 trial
Ankylosing spondylitis
Phase 1/2 · Enrolling by invitation · 1 trial

Readouts due

27 Sept 2027
An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis
Phase 2/3 · Recruiting

Stopped

NCT01676441 · Terminated · Spinal cord injury
sponsor decision (confidential)
NCT01045382 · Terminated · Multiple myeloma
recruitment too slow
NCT04519671 · Terminated · Crohn's disease
PI left Cleveland Clinic
NCT04519684 · Terminated · Crohn's disease
PI left Cleveland Clinic
NCT04519697 · Terminated · Crohn's disease
PI left Cleveland Clinic

Development

Companies: Mesoblast Rexlemestrocel-L Phase 3 chronic low back pain
Longeveron Laromestrocel Phase 2 hypoplastic left heart syndrome, aging frailty